When to treat prostate cancer patients based on their PSA dynamics

IIE Transactions on Healthcare Systems Engineering

Volumn 2, Issue 1, 2012, Pages 62-77

  Lavieri, Mariel S ^a   Puterman, Martin L ^b   Tyldesley, Scott ^c   Morris, William J ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bayesian updating; Cancer; cluster analysis; disease modeling; Kalman filter; medical decision making

Indexed keywords

ANTIANDROGEN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CLINICAL DECISION MAKING; CONFIDENTIALITY; HORMONAL THERAPY; HUMAN; MATHEMATICAL MODEL; MEASUREMENT ERROR; NORMAL DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION;

EID: 84981266577     PISSN: 19488300     EISSN: 19488319     Source Type: Journal    
DOI: 10.1080/19488300.2012.666631     Document Type: Article

References (38)

1. Agresti, A. 1996. An Introduction to Categorical Data Analysis, New York: John Wiley & Sons, Inc.
2. Alagoz, O., Maillart, L. M., Schaefer, A. J. and Roberts, M. S. 2007. Determining the acceptance of cadaveric livers using an implicit model of the waiting list. Operations Research, 55(1): 24-36.
3. American Cancer Society. 2008. Detailed Guide: Prostate Cancer., Atlanta, GA: American Cancer Society. [online]. Available at: www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt = 36
4. BC Cancer Agency. 2009. Prostate Cancer: BC Cancer Agency, Vancouver, BC: BC Cancer Agency. [online]. Available at: www.bccancer.bc.ca
5. Celeux, G. and Soromenho, G. 1996. An entropy criterion for assessing the number of clusters in a mixture model. Journal of Classification, 13: 195-212.
6. D'Amato, R., D'Aquila, R. and Wein, L. 2000. Management of antiretroviral therapy for HIV infection: analyzing when to change therapy. Management Science, 50(10): 1200-1213.
7. Denham, J., Steigler, A., Wilcox, C., Lamb, D., Joseph, D., Atkinson, C., Matthews, J., Tai, K-H., Spry, N., Christie, D., Gleeson, P. S., Greer, P. and D'Este, C. 2008. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomized controlled trial. The Lancet Oncology, 9(11): 1058-1068.
8. Fieller, E. C. 1932. The distribution of the index in a normal bivariate population. Biometrika, 24: 428-440.
9. Fraley, C. and Raftery, A. E. 1998. How Many Clusters? Which Clustering Method? Answers via Model-Based Cluster Analysis. The Computer Journal, 41(8): 578-588.
10. Fraley, C. and Raftery, A. E. 2002. Model-based clustering, discriminant analysis, and density estimation. Journal of the American Statistical Association, 97: 611-631.
11. Fraley, C. and Raftery, A. E. 2006. MCLUST version 3 for R: Normal mixture modeling and model-based clustering, University of Washington, Department of Statistics, Seattle, WA. Technical Report 504
12. Gleave, M. E., La Bianca, S. and Goldenberg, S. L. 2000. Neodajuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls. Prostate Cancer and Prostatic Diseases, 3: 136-144.
13. Goldie, J. H. and Coldman, A. J. 1979. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports, 63(11-12): 1727-1733.
14. Harvey, A. 1991. Forecasting Structural Time Series Models and the Kalman Filter., 100-167. Cambridge, UK: Cambridge University Press.
15. Heymann, J. J., Benson, M. C., O'Toole, K. M., Malyszko, B., Brody, R., Vecchio, D., Schiff, P. B., Mansukhani, M. M. and Ennis, R. D. 2007. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. Journal of Clinical Oncology, 25(1): 77-84.
16. Hinkley, D. V. 1969. On the ratio of two correlated normal random variables. Biometrika, 56(3): 635-639.
17. Horwitz, E. M. and Hanks, G. E. 2000. "Hormonal therapy combined with radiation or surgery in treatment of locally advanced non-metastatic prostate cancer". In Comprehensive Textbook of Genitourinary Oncology, Edited by: Vogelzang, N. J., Scardino, P. T., Shipley, W. U., Coffey, D. S. and Miles, B. J. 782-789. Philadelphia, PA: Lippincott Williams & Wilkins.
18. Inoue, L. I. T., Etzioni, R., Morrell, C. and Müller, P. 2008. Modeling disease progression with longitudinal marker. Journal of the American Statistical Association, 103(481): 259-270.
19. Knobbe, E. J. and Buckingham, B. 2005. The extended Kalman Filter for continuous glucose monitoring. Diabetes Technology & Therapeutics, 7(1): 15-27.
20. Kristiansen, N. K., Sjöström, S.-O. and Nygaard, H. 2005. Urinary bladder volume tracking using a Kalman Filter. Medical and Biological Engineering and Computing, 43(3): 331-334.
21. Kurt, M., Denton, B. T., Schaefer, A. J., Shah, N. D. and Smith, S. A. 2011. The structure of optimal statin initiation policies for patients with type 2 diabetes. IIE Transactions on Healthcare Systems Engineering, 1: 49-65.
22. Lavieri, M. S. 2009. Nursing workforce planning and radiation therapy treatment decision making: two healthcare operations research applications, Ph.D thesis. University of British Columbia, Vancouver, BC, Canada.
23. Lavieri, M. S., Puterman, M. L. and Tyldesley, S. 2012. Modeling of PSA dynamics of prostate cancer patients receiving neoadjuvant hormone therapy prior to radiation therapy. Working manuscript
24. Law, N. J., Taylor, J. and Sandler, H. 2002. The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure. Biostatistics, 3(4): 547-563.
25. Lin, H., Turnbull, B. W., McCulloch, C. E. and Slate, E. H. 2002. Latent class models for joint analysis of longitudinal biomarker and event process data. Journal of the American Statistical Association, 97(457): 53-65.
26. Makarov, D. V., Trock, B. J., Humphreys, E. B., Mangold, L. A., Walsh, P. C., Epstein, J. I. and Partin, A. W. 2007. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology, 69(6): 1095-1101.
27. Morrell, C. H., Sheng, S. L. and Brant, L. J. 2011. A comparative study of approaches for predicting prostate cancer from longitudinal data in communications. Statistics-Simulation and Computation, 40(9): 1494-1513.
28. Morris, W. J. 2009. Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy. NCI Clinical Trials Inventory, National Cancer Institute [online]. Available at: www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=453036&version = HealthProfessional&protocolsearchid = 6093623 (accessed November 2009)
29. National Cancer Institute. 2011. Cancer Statistics Home Page-National Cancer Institute Available at: www.cancer.gov/statistics/ (accessed March 2012)
30. Niblock, P., Pickles, T. and the British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. 2006. Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: the importance of monitoring. International Journal of Radiation Oncology Biology Physics, 65(1): 59-64.
31. Oehlert, G. W. 1992. A note on the Delta Method. American Statistician, 46(1): 27-29.
32. Parker, R. S., Doyle, F. J. III and Peppas, N. A. 1999. A model-based algorithm for blood glucose control in type i diabetic patients. Biomedical Engineering, IEEE Transactions, 46(2): 148-157.
33. Partin, A. W. and Carter, B. 2000. "Use of prostate-specific antigen density and velocity". In Comprehensive Textbook of Genitourinary Oncology, Edited by: Vogelzang, N. J., Scardino, P. T., Shipley, W. U., Coffey, D. S. and Miles, B. J. 650-654. Philadelphia, PA: Lippincott Williams & Wilkins.
34. Rehbinder, H., Forsgren, C. and Löf, J. 2004. Adaptive radiation therapy for compensation of errors in patient setup and treatment delivery. Medical Physics, 31(12): 3363-3371.
35. Sandblom, G., Holmberg, L., Damber, J. E., Hugosson, J., Johansson, J. E., Lundgren, R., Mattsson, E., Nilsson, J. and Varenhorst, E. 2002. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups. Scandinavian Journal of Urology & Nephrology, 36(2): 106-112.
36. Shechter, S. M., Bailey, M. D., Schaefer, A. J. and Roberts, M. S. 2008. The optimal time to initiate HIV therapy under ordered health states. Operations Research, 56(1): 20-33.
37. Yu, M., Taylor, J. M. G. and Sandler, H. M. 2008. Individual prediction in prostate cancer studies using a joint longitudinal survival-cure model. Journal of the American Statistical Association, 103(481): 178-187.
38. Zhu, H. and Rohwer, R. 1996. Bayesian regression filters and the issue of priors. Neural Computing & Applications, 4(3): 130-142.